Photodynamic therapy and fluorescent diagnostics of head and neck cancer with second-generation photosensitizers

Elena G. Vakulovskaya

doi:10.1117/12.640039

7 December 2006 Photodynamic therapy and fluorescent diagnostics of head and neck cancer with second-generation photosensitizers

Elena G. Vakulovskaya

Author Affiliations +

Proceedings Volume 5973, Current Research on Laser Use in Oncology: 2000-2004; 597308 (2006) https://doi.org/10.1117/12.640039
Event: Current Research on Laser Use in Oncology: 2000-2004, 2004, Moscow, Russian Federation

Abstract

Photodynamic Therapy (PDT) and fluorescent diagnostics (FD) using Photosense was provided in 50 patients with head and neck cancer T1-3 stage, in 89 patients with skin cancer, using Radaclorine (RC) in 42 patients with T1-4 stage basal cell carcinoma (BCC),in 6 patients with oral cancer. Detection of borders of tumor, intensity of accumulation of photosensitizers in tumor, normal tissues were done by Spectral-fluorescent Complex. We've got fluorescence of a11 tumors and additional fluorescence zones were found with cytological verification. We used semiconductive lasers: Milon - λ = 660+2nm, light dose 200 - 300 J/cm² and Biospec (λ=672+2nm), multiple laser surface and interstitial irradiation with total light dose till 400-600 J/cm². After PDT with PS in head and neck cancer we've had complete response (CR) in 66.0% and partial response (PR) in 30.0%, with RC CR in BCC T1-2NOMO - 92.9%, in recurrencies CR - 60,6%, PR - 39,4%. The efficacy of PDT with PS was higher (CR - 86.7%, PR - 13,3%) and the recurrence rate in 6 months lower. Our experience show pronounced efficacy of PDT for head and neck tumors of different localization and histology, FD is providing diagnostically significant information, demonstrated high sensitivity and specificity.

Citation Download Citation

Elena G. Vakulovskaya "Photodynamic therapy and fluorescent diagnostics of head and neck cancer with second-generation photosensitizers", Proc. SPIE 5973, Current Research on Laser Use in Oncology: 2000-2004, 597308 (7 December 2006); https://doi.org/10.1117/12.640039

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available